How Should Molecular Markers and Magnetic Resonance Imaging Be Used in the Early Detection of Prostate Cancer?

Eur Urol Oncol. 2022 Apr;5(2):135-137. doi: 10.1016/j.euo.2021.01.010. Epub 2021 Feb 16.

Abstract

The literature gives limited data or guidance on how to select or combine biomarkers and magnetic resonance imaging (MRI) for the early detection of prostate cancer. We strongly recommend prospective studies large enough to address questions such as the properties of biomarkers in cases with high versus low Prostate Imaging-Reporting and Data System scores or the correlation between biomarkers and MRI, and that evaluate results in the context of reasonable clinical scenarios.

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Biomarkers
  • Early Detection of Cancer
  • Humans
  • Image-Guided Biopsy* / methods
  • Magnetic Resonance Imaging / methods
  • Male
  • Prospective Studies
  • Prostatic Neoplasms* / diagnostic imaging
  • Prostatic Neoplasms* / pathology

Substances

  • Biomarkers